These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
57 related articles for article (PubMed ID: 1980369)
41. An early phase II clinical trial of remoxipride in schizophrenia with measurement of plasma neuroleptic activity. Chouinard G; Turnier L Psychopharmacol Bull; 1986; 22(1):267-71. PubMed ID: 2873615 [No Abstract] [Full Text] [Related]
42. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Akhondzadeh S; Safarcherati A; Amini H Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232 [TBL] [Abstract][Full Text] [Related]
43. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636). Hamner MB; Arvanitis LA; Miller BG; Link CG; Hong WW Psychopharmacol Bull; 1996; 32(1):107-10. PubMed ID: 8927658 [TBL] [Abstract][Full Text] [Related]
44. [FDA phase II and phase III drug evaluation of antipsychotic agents]. Yagi K Seishin Shinkeigaku Zasshi; 1990; 92(9):584-92. PubMed ID: 1980369 [No Abstract] [Full Text] [Related]
45. [Difficulties of evaluation of the results of drug treatment of schizophrenia]. Welbel L Psychiatr Pol; 1980; 14(1):51-7. PubMed ID: 6102774 [No Abstract] [Full Text] [Related]
46. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Woods SW; Gueorguieva RV; Baker CB; Makuch RW Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728 [TBL] [Abstract][Full Text] [Related]